bilal yousuf The focus of the industry on living beings that are human and highly controlled standards provide unique considerations for business leaders. These attributes make the industry an ideal incubator for creativity, leading to significant breakthroughs that have increased the yield of agricultural crops, developed biofuels and led to life-saving pharmaceutical products.
Start-up biotech companies have many options when it comes to revenue generation strategies, with most choosing either a technology partnership or an asset creation and out-licensing approach. Technology partnering can generate more revenues with less risk to the financials, while an asset creation and out-licensing strategy yields higher returns when it’s successful. A growing number of biotechs in the early stages of research employ a hybrid strategy that combines both strategies.
If you choose to go with an approach to development that is oriented towards product will be successful commercially in the event that they can bring their pipeline to the appropriate stage and attract a large Pharma partner or an investor with deep pockets. This can be an expensive venture. It is essential to balance the opportunistic approach of using outside resources and making appropriate scientific choices regarding homegrown projects.
The “platform” model is an alternative alternative to generate revenue. It’s a less costly option than the product-oriented development however it carries significant risk. In this model biotechs have the ability to develop their own platform technology, before teaming with pharma giants to www.genotec-frankfurt.de/biotechnological-synthesis-of-remedies/ create a portfolio of drug-discovery projects that target specific diseases (i.e. disease that is x in biology, y). This is the model Advinus Therapeutics and a few others have followed.
